Gilead Acquires Nimbus' Biotech Drugs for NASH Treatment


Apr 12, 2016

Gilead Sciences announced it has acquired Nimbus Therapeutics' Nimbus Apollo division, a line of biotech drugs in a deal potentially worth $1.2 billion, according to Bloomberg.

With the purchase of  the drug line, the biotechnology giant is expanding its development portfolio of treatments for the fatty liver disease known as non-alcoholic steatohepatitis, or NASH. Gilead acquired the Nimbus Apollo division for $400 million upfront, plus up to $800 million if Nimbus’ drugs successfully make it through the development process.

The drug line consists of an acetyl-CoA carboxylase (ACC) inhibitor called NDI-010976.

“These molecules will complement and further strengthen Gilead’s pipeline and capabilities to advance a broad clinical program in NASH,” Norbert Bischofberger, Gilead’s chief scientific officer, said in a statement announcing the deal.

Phase-one trial results for NDI-010976 are due to be presented in a couple of weeks at the annual International Liver Congress.

Click here to read the full report from Bloomberg.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments